



SC&A Status Update on Comments Matrix, Review of Petitioner Submissions, and Other Matters

Stephen L. Ostrow, PhD, SC&A, Inc.

Advisory Board on Radiation and Worker Health

August 8, 2024



History of SEC-00256 reviews & discussions

- ◆ 10/13/2021: NIOSH SEC-00256 Petition Evaluation Report (ER)
- ◆ 12/8/2021: ABRWH meeting. NIOSH presented ER; SC&A tasked to review
- ◆ 12/8/2022: ABRWH meeting. SC&A presented the status of ER review
- ◆ 6/16/2023: SC&A Interim Review Report
- ◆ 11/20/2023: WG meeting
 - NIOSH presentation of ER
 - SC&A presentation of Interim Review Report
 - NIOSH presentation on its response to SC&A's Interim Review Report
- ◆ 12/7/2023: ABRWH meeting. SC&A presentation of Interim Review Report

SC&A tasking

- ◆ The WG recognizes that the ER review process is ongoing, and assessments are subject to revision
- ◆ 12/8/2021 ABRWH meeting: Review ER
- ◆ 11/20/2023 WG meeting set several tasks:
 - Develop a Comments Matrix to facilitate tracking status
 - Assess new reports, claimant interviews, and petitioner submittals
 - Evaluate all new information from data collection activities after the June 2023 SC&A Interim Review Report closing (circa March 2023)
 - Identify any areas of concern for dose reconstruction
 - Supplement the SC&A Interim Review Report with follow-up report

Comments matrix

- ◆ Matrix includes, from the SC&A Interim Review Report:
 - Observations
 - General petitioner issues
 - Petitioner comments (including some after the report but before the 11/20/23 WG meeting)
- ◆ Matrix status: SC&A is finalizing its internal review and plans to send a draft for comment/revision to the WG and NIOSH.

New reports, claimant interviews, submittals

- ◆ There have been no new reports or claimant interviews since issuance of the SC&A Interim Review Report; SC&A will participate in any interview activities initiated by NIOSH.
- ◆ SC&A is identifying, collecting, summarizing, and commenting on all transmittals made by claimants or their representatives from 2022–present with the goals of:
 - Gathering all submittals in one convenient table
 - Ensuring that all relevant petitioner concerns are adequately addressed
 - Serving as a resource for any areas requiring further investigation
- ◆ **Status: Ongoing**

Petitioner documents submitted

Year	Submittals to DFO	Documents Submitted
2022	2	7
2023	11	42
2024 (to July 1st)	7	7
Total	20	56

Petitioner documents review table format

DFO Submittal Date to WG	Document Date ^(a)	File ID: (number), name ^(b)	Contents	Comments
date	date	(number), name	text	text

- (a) A single transmittal to the DFO may contain multiple documents
- (b) SC&A has assigned document numbers for convenience in referring to the documents; e.g. (23-7) indicates the 7th document of 2023. “Name” is the actual name of the transmitted file.

Topics of special interest

- ◆ As a result of petitioner, WG, and SC&A interests, SC&A has been investigating several subjects in more detail, including:
 - Plutonium handling operations, the possibility of the presence of unencapsulated plutonium, and the adequacy of bioassay information
 - Uranium bioassay sufficiency
 - Assess annual tritium inventories and device production records to see if there is a correlation to dosimetry records
 - Radioactive contamination not accounted for in the ER
 - Neutron generator details and exposure data
 - Radioisotope thermoelectric generators details and exposure data
 - Early plant operations and monitoring practices
 - Heather project
 - Research and development operations not accounted for in the ER

Data collection activities assessment

- ◆ SC&A is examining “new” documents from data captures placed in the Site Research Data Base (SRDB) (fall 2023) to inform reviews of subjects important to evaluation of the ER
- ◆ This activity has only recently begun following improved access to and search capabilities of the SRDB
- ◆ Status: Ongoing

Supplemental review report

- ◆ At some point in the SEC-0256 ER review cycle, SC&A will issue a supplement to its June 2023 Interim Review Report incorporating new material and findings
- ◆ Status: Not begun

Path forward summary

- ◆ Update Comments Matrix as receive responses to the items
- ◆ Continue all investigations (e.g., data completeness, sources of exposure not covered in the ER)
- ◆ Evaluate new information from data collection activities and petitioner submittals
- ◆ Identify and pursue areas warranting further investigation
- ◆ As they become available, access NOCTS, BRS, and CATI reports to determine any additional SEC-related issues
- ◆ Issue a supplemental report on findings



Questions?